company background image
RDNT

RadNetNasdaqGM:RDNT Stock Report

Market Cap

US$1.5b

7D

3.6%

1Y

94.8%

Updated

28 Sep, 2021

Data

Company Financials +
RDNT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance3/6
Financial Health2/6
Dividends0/6

RDNT Overview

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States.

RadNet Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RadNet
Historical stock prices
Current Share PriceUS$28.85
52 Week HighUS$14.31
52 Week LowUS$38.84
Beta1.67
1 Month Change-7.18%
3 Month Change-14.37%
1 Year Change94.80%
3 Year Change99.79%
5 Year Change291.45%
Change since IPO2,785.00%

Recent News & Updates

Shareholder Returns

RDNTUS HealthcareUS Market
7D3.6%-0.4%2.0%
1Y94.8%33.0%32.8%

Return vs Industry: RDNT exceeded the US Healthcare industry which returned 33% over the past year.

Return vs Market: RDNT exceeded the US Market which returned 32.8% over the past year.

Price Volatility

Is RDNT's price volatile compared to industry and market?
RDNT volatility
RDNT Beta1.67
Industry Beta0.87
Market Beta1

Stable Share Price: RDNT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: RDNT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19856,420Howard Bergerhttps://www.radnet.com

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems.

RadNet Fundamentals Summary

How do RadNet's earnings and revenue compare to its market cap?
RDNT fundamental statistics
Market CapUS$1.53b
Earnings (TTM)US$24.44m
Revenue (TTM)US$1.26b

62.7x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDNT income statement (TTM)
RevenueUS$1.26b
Cost of RevenueUS$1.02b
Gross ProfitUS$240.67m
ExpensesUS$216.22m
EarningsUS$24.44m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.46
Gross Margin19.16%
Net Profit Margin1.95%
Debt/Equity Ratio253.9%

How did RDNT perform over the long term?

See historical performance and comparison

Valuation

Is RadNet undervalued compared to its fair value and its price relative to the market?

9.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RDNT ($28.85) is trading below our estimate of fair value ($31.86)

Significantly Below Fair Value: RDNT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: RDNT is poor value based on its PE Ratio (62.7x) compared to the US Healthcare industry average (22.4x).

PE vs Market: RDNT is poor value based on its PE Ratio (62.7x) compared to the US market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: RDNT is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: RDNT is overvalued based on its PB Ratio (7.8x) compared to the US Healthcare industry average (3.2x).


Future Growth

How is RadNet forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

16.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDNT's forecast earnings growth (16.7% per year) is above the savings rate (2%).

Earnings vs Market: RDNT's earnings (16.7% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: RDNT's earnings are forecast to grow, but not significantly.

Revenue vs Market: RDNT's revenue (5.8% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: RDNT's revenue (5.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RDNT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has RadNet performed over the past 5 years?

0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RDNT has high quality earnings.

Growing Profit Margin: RDNT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RDNT's earnings have grown by 0.4% per year over the past 5 years.

Accelerating Growth: RDNT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RDNT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (32.2%).


Return on Equity

High ROE: RDNT's Return on Equity (14.4%) is considered low.


Financial Health

How is RadNet's financial position?


Financial Position Analysis

Short Term Liabilities: RDNT's short term assets ($334.9M) do not cover its short term liabilities ($381.3M).

Long Term Liabilities: RDNT's short term assets ($334.9M) do not cover its long term liabilities ($1.4B).


Debt to Equity History and Analysis

Debt Level: RDNT's debt to equity ratio (253.9%) is considered high.

Reducing Debt: RDNT's debt to equity ratio has reduced from 1688.4% to 253.9% over the past 5 years.

Debt Coverage: RDNT's debt is well covered by operating cash flow (21.2%).

Interest Coverage: RDNT's interest payments on its debt are not well covered by EBIT (2.7x coverage).


Balance Sheet


Dividend

What is RadNet current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RDNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RDNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Howard Berger (75 yo)

34.67yrs

Tenure

US$2,835,761

Compensation

Dr. Howard G. Berger, M.D., serves as the President and Chief Financial Officer of Image Medical Corporation. Dr. Berger has been the Chief Executive Officer and President at RadNet, Inc. and its predecess...


CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD2.84M) is about average for companies of similar size in the US market ($USD3.66M).

Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RDNT's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: RDNT's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RDNT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

RadNet, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: RadNet, Inc.
  • Ticker: RDNT
  • Exchange: NasdaqGM
  • Founded: 1985
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.533b
  • Shares outstanding: 53.14m
  • Website: https://www.radnet.com

Number of Employees


Location

  • RadNet, Inc.
  • 1508, 1510 and 1516 Cotner Avenue
  • Los Angeles
  • California
  • 90025
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/28 23:17
End of Day Share Price2021/09/28 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.